
Two prominent conferences covering Long COVID, postural orthostatic tachycardia syndrome (POTS), and related diseases occurred this past week. Early results from trials were shared at both the American Autonomic Society (AAS)’s 37th International Symposium on the Autonomic Nervous System in San Diego, California, and the 4th Long COVID International Conference in Nice, France.
American Autonomic Society symposium:
- A small phase 2 clinical trial found baloncibart improved heart rate and orthostatic intolerance in people with POTS, according to early results from the drug’s developer, Regeneron. Balocibart is an investigational monoclonal antibody, which blocks a specific pathway to prevent vasodilatation, or blood vessel widening. The trial included 82 participants who were given a one-time subcutaneous dose of either 150 or 450 milligrams of the drug, or received a placebo. Researchers measured change in heart rate from laying down to standing as the primary endpoint, and found significant improvement in this measure as well as participant-reported POTS symptoms. Regeneron plans a phase 3 clinical trial in 2027.
- Intravenous immunoglobulin (IVIG) did not significantly improve symptoms of Long COVID-related POTS, according to unpublished results from RECOVER. The study, a platform trial called RECOVER-AUTONOMIC, included 200 people with a severe POTS following COVID-19, who received either a form of IVIG called Gamunex-C or intravenous saline, for nine months. (The RECOVER press release incorrectly stated three months.) RECOVER listed their primary endpoint in the original protocol as the change in orthostatic intolerance symptoms measured by a questionnaire. The trial also included arms for usual care and coordinated care (which included physical therapy). This is the latest first-round RECOVER trial to have a null result. The other arm of RECOVER-AUTONOMIC that tested the heart failure drug ivabradine also failed, according to the NIH.
4th Long COVID International Conference:
- Many talks at the conference discussed research into Long COVID biomarkers, including markers of potential SARS-CoV-2 persistence, immune system dysfunction, and herpesvirus reactivation. For example, Johan van Weyenbergh and Chenyu Liu from KU Leuven in Belgium shared updates from their group’s viral persistence research and Morgane Bomsel from Institut Cochin in France discussed the potential role of megakaryocytes, a type of bone marrow cell that produces blood clots, in developing Long COVID.
- Genetics research was another major theme at the conference. Vilma Lammi shared findings from the Long COVID Host Genetics Initiative, a global collaboration bringing together genetic data from nearly 20 countries. Sindhu Mohandas from the Children’s Hospital of Los Angeles shared preliminary results from a genetic study looking specifically at children with Long COVID. Erika Elder from Johns Hopkins University shared findings suggesting that family history could contribute to developing dysautonomia after COVID-19.
- Other talks discussed clinical care for Long COVID, including several presentations about caring for children. David Kelly from the Organization for Economic Co-operation and Development (OECD) summarized a recent report on the costs and care for Long COVID across the 38 OECD member countries, highlighting the disease’s significant burden and lack of training for physicians. Fleur Hiensch from the University of Amsterdam shared lessons from the Netherlands’ Pediatric Expertise Centers for children with Long COVID.
- Some researchers gave updates on clinical trials. Jacqueline Becker from Mount Sinai discussed the institution’s pilot study of microtesla magnetic therapy (MMT), a device that targets inflammation in the brain. Building on the pilot study’s promising results, Becker and her colleagues are planning a larger clinical trial that they hope to start in early 2027, she said.
Betsy Ladyzhets contributed reporting on the Long COVID International Conference.













